Cody Tranbarger is biotech entrepreneur and investor. Cody is currently the Co-Founder of Revision Bio, a next-generating gene writing company, and holds a Consultant / Entrepreneur-in-Residence role at Atlas Venture, a biotech venture creation firm. Previously, Cody served as Analyst and Head of Genetic Medicines at Casdin Capital, where he led the firm’s investing effort focused on next-generation therapeutic technologies, such as cell and gene therapies. Cody began his career as an Investment Banking Analyst at Goldman Sachs, where he focused on the evaluation and execution of M&A and financing transactions for clients across the biotech sector. Cody graduated magna cum laude from Amherst College with a B.A. in Biology and Economics, and is an MS/MBA Biotechnology: Life Sciences candidate at Harvard Business School and Harvard Kenneth C. Griffin Graduate School of Arts and Sciences.
Cure Rare Disease, a non-profit organization (Tax ID number 82-2473513), is qualified as a tax-exempt organization under section 501(c)(3) of the IRS and has been designated as a “public charity” under section 170.
© CURE RARE DISEASE. ALL RIGHTS RESERVED.
.png)
© CURE RARE DISEASE.ALL RIGHTS RESERVED.
